Last reviewed · How we verify
Valsartan, hydrochlorothiazide and amlodipine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Valsartan, hydrochlorothiazide and amlodipine (Valsartan, hydrochlorothiazide and amlodipine) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Valsartan, hydrochlorothiazide and amlodipine TARGET | Valsartan, hydrochlorothiazide and amlodipine | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Valsartan, hydrochlorothiazide and amlodipine CI watch — RSS
- Valsartan, hydrochlorothiazide and amlodipine CI watch — Atom
- Valsartan, hydrochlorothiazide and amlodipine CI watch — JSON
- Valsartan, hydrochlorothiazide and amlodipine alone — RSS
Cite this brief
Drug Landscape (2026). Valsartan, hydrochlorothiazide and amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-hydrochlorothiazide-and-amlodipine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab